Magnesium carbonate
Identification
- Name
- Magnesium carbonate
- Accession Number
- DB09481
- Description
Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach Label.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Magnesium carbonate (DB09481)
- Weight
- Average: 84.314
Monoisotopic: 83.969785764 - Chemical Formula
- CMgO3
- Synonyms
- Magnesio carbonato
- External IDs
- C.I. 77713
Pharmacology
- Indication
Used as an over the counter antacid 5.
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Neutralizes acid in the stomach 5.
- Mechanism of action
Magnesium carbonate reacts with hydrochloric acid in the stomach to form carbon dioxide and magnesium chloride thus neutralizing excess acid in the stomach 5.
Target Actions Organism UGlutamate (NMDA) receptor blockerHumans - Absorption
About 40-60% of magnesium is absorbed following oral administration 5. Percent absorption decreases as dose increases.
- Volume of distribution
Vd for magnesium is 0.2-0.4L/kg 5. About 50% distributes to bone.
- Protein binding
30% of magnesium is bound to proteins 5.
- Metabolism
Magnesium does not appear to be metabolized in any way 5.
- Route of elimination
Primarily eliminated in urine 5.
- Half-life
Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult 5.
- Clearance
Maximum magnesium clearance is directly proportional to creatinine clearance 5.
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
During overdose, magnesium impairs neuromuscular transmission resulting in weakness and hypoflexia 5.
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbacavir Abacavir may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Acarbose Acarbose may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Acetaminophen Magnesium carbonate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium carbonate. Acetophenazine Magnesium carbonate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Aclidinium Aclidinium may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Acrivastine Magnesium carbonate may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Magnesium carbonate basic YQO029V1L4 39409-82-0 UOVKYUCEFPSRIJ-UHFFFAOYSA-D - Active Moieties
Name Kind UNII CAS InChI Key Magnesium cation ionic T6V3LHY838 22537-22-0 JLVVSXFLKOJNIY-UHFFFAOYSA-N Carbonate ion ionic 7UJQ5OPE7D 3812-32-6 BVKZGUZCCUSVTD-UHFFFAOYSA-L - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataCepasium Tab 100mg Tablet Oral Laboratoires Cortunon Inc. 1979-12-31 2002-08-23 Canada 
Humco Dewees Carminative Suspension 50 mg/1mL Oral Humco Holding Group. Inc. 1998-03-25 Not applicable US 
Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Acid Gone Antacid Magnesium carbonate (358 mg/15mL) + Aluminum hydroxide (95 mg/15mL) Liquid Oral Major 2004-12-30 Not applicable US Acid Gone Antacid Extra Strength Magnesium carbonate (105 mg/1) + Aluminum hydroxide (160 mg/1) Tablet, chewable Oral Major Pharmaceuticals 2014-06-06 Not applicable US Acid Gone Antacid Extra Strength Magnesium carbonate (105 mg/1) + Aluminum hydroxide (160 mg/1) Tablet, chewable Oral Avera McKennan Hospital 2015-07-09 2017-05-24 US Aluminum hydroxide and Magnesium carbonate Magnesium carbonate (105 mg/1) + Aluminum hydroxide (160 mg/1) Tablet, chewable Oral Simpex Pharma Pvt. Ltd 2018-02-09 Not applicable US Antacid Magnesium carbonate (105 mg/1) + Aluminum hydroxide (160 mg/1) Tablet, chewable Oral Meijer Distribution 1996-09-05 2016-12-26 US Antacid - Tab Magnesium carbonate (172.2 mg) + Calcium carbonate (327.8 mg) Tablet Oral Swiss Herbal Remedies Ltd. 1996-09-04 2003-09-10 Canada Antacid Extra Strength Magnesium carbonate (105 mg/1) + Aluminum hydroxide (160 mg/1) Tablet, chewable Oral Rite Aid 1997-08-07 2012-08-24 US Aspirin Plus Stomach Guard Ext.stgth.caplet Magnesium carbonate (52.3 mg) + Acetylsalicylic acid (500 mg) + Calcium carbonate (246.2 mg) + Magnesium oxide (96.9 mg) Tablet Oral Sterling Winthrop Inc. 1994-12-31 1996-09-10 Canada Aspirin Plus Stomach Guard Extra Strength Magnesium carbonate (52.32 mg) + Acetylsalicylic acid (500 mg) + Calcium carbonate (246.22 mg) + Magnesium oxide (96.95 mg) Tablet Oral Bayer Inc Consumer Care 1995-12-31 1998-09-28 Canada Aspirin Plus Stomach Guard Tab Magnesium carbonate (34 mg) + Acetylsalicylic acid (325 mg) + Calcium carbonate (160 mg) + Magnesium oxide (63 mg) Tablet Oral Sterling Winthrop Inc. 1994-12-31 1996-09-10 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image MagneBind 400 Rx Magnesium carbonate (115 mg/1) + Calcium carbonate (80 mg/1) + Folic acid (1 mg/1) Tablet, film coated Oral Carilion Materials Management 1999-10-18 Not applicable US MagneBind 400 Rx Magnesium carbonate (115 mg/1) + Calcium carbonate (80 mg/1) + Folic acid (1 mg/1) Tablet, film coated Oral Nephro-Tech, Inc. 1999-10-18 Not applicable US
Categories
- ATC Codes
- A02AA01 — Magnesium carbonate
- A02AA — Magnesium compounds
- A02A — ANTACIDS
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- V03AE — Drugs for treatment of hyperkalemia and hyperphosphatemia
- V03A — ALL OTHER THERAPEUTIC PRODUCTS
- V03 — ALL OTHER THERAPEUTIC PRODUCTS
- V — VARIOUS
- Drug Categories
- Agents that produce neuromuscular block (indirect)
- Alimentary Tract and Metabolism
- Aluminum and magnesium containing antacids
- Antacids
- Bleaching Agents
- Calculi Dissolution Agent
- Compounds used in a research, industrial, or household setting
- Drugs for Acid Related Disorders
- Drugs for Constipation
- Drugs for Treatment of Hyperkalemia and Hyperphosphatemia
- Drugs that are Mainly Renally Excreted
- Elements
- Gastric Acid Lowering Agents
- Hygroscopic Agents
- Laxatives
- Laxatives, magnesium containing
- Magnesium Compounds
- Metal cations
- Metal divalent cations
- Metals
- Metals, Alkaline Earth
- Metals, Light
- Noxae
- Osmotic Laxatives
- Oxidants
- Toxic Actions
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic carbonic acids and derivatives
- Sub Class
- Organic carbonic acids
- Direct Parent
- Organic carbonic acids
- Alternative Parents
- Carbonate salts / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Carbonate salt / Carbonic acid / Carbonyl group / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organic salt / Organooxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- magnesium salt, one-carbon compound, carbonate salt (CHEBI:31793)
Chemical Identifiers
- UNII
- 0IHC698356
- CAS number
- 546-93-0
- InChI Key
- ZLNQQNXFFQJAID-UHFFFAOYSA-L
- InChI
- InChI=1S/CH2O3.Mg/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2
- IUPAC Name
- magnesium(2+) ion carbonate
- SMILES
- [Mg++].[O-]C([O-])=O
References
- General References
- de Baaij JH: The art of magnesium transport. Magnes Res. 2015 Jul-Sep;28(3):85-91. doi: 10.1684/mrh.2015.0388. [PubMed:26446763]
- Jahnen-Dechent W, Ketteler M: Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163. [PubMed:26069819]
- Nikolaev MV, Magazanik LG, Tikhonov DB: Influence of external magnesium ions on the NMDA receptor channel block by different types of organic cations. Neuropharmacology. 2012 Apr;62(5-6):2078-85. doi: 10.1016/j.neuropharm.2011.12.029. Epub 2012 Jan 12. [PubMed:22261381]
- CDC NIOSH: MgCO3 [Link]
- Toxnet [Link]
- External Links
- KEGG Compound
- C12893
- PubChem Compound
- 11029
- PubChem Substance
- 347827861
- ChemSpider
- 10563
- 29155
- ChEBI
- 31793
- ChEMBL
- CHEMBL1200736
- Wikipedia
- Magnesium_carbonate
- FDA label
- Download (129 KB)
- MSDS
- Download (79.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Dyspepsia 1 3 Completed Treatment Gastro-esophageal Reflux Disease (GERD) 1 3 Terminated Other Gastro-esophageal Reflux Disease (GERD) 1 2, 3 Completed Treatment Chronic Kidney Disease (CKD) / Hyperphosphataemia 1 1 Completed Basic Science Gastro-esophageal Reflux Disease (GERD) 2 1 Completed Treatment Healthy Volunteers 1 Not Available Completed Diagnostic Gastroesophageal Reflux 1 Not Available Unknown Status Supportive Care Secondary Hyperparathyroidism (SHPT) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Oral 2.39 g Tablet, film coated Oral 15 mg Tablet, effervescent Oral 15 mg Tablet, chewable Oral 30 mg Granule Oral 400 mg Tablet, chewable Oral 680 mg Tablet Oral Powder, for solution Oral 8.155 G Powder Oral 670 mg Powder Oral Suspension Oral Tablet Oral 680 mg Suspension Oral 150 mg/5ml Suspension Oral 600 mg/5ml Liquid Oral Solution Oral 3.3 % w/v Suspension Oral 50 mg/1mL Granule Oral Granule Oral 670 mg/6.1g Solution Oral 600 mg/15mL Tablet, film coated Oral Powder, for solution Oral 670 mg Powder Oral 71 mg Tablet Oral 71 mg Tablet Transmucosal 71 mg Tablet Oral Granule, for solution Oral 670 mg Granule Oral 670 mg Suspension Oral 250 mg Solution Oral 3.33 %w/w Tablet Oral 270 mg Tablet, chewable Oral 270 mg Tablet, coated Oral 435 mg Tablet, film coated Oral 435 mg Suspension Oral 250 mg/5ml Solution Irrigation Lozenge Oral 80 mg Lozenge Oral 680 mg Suspension Oral 150 mg Suspension Oral 680 mg Solution Oral 1 g/5ml Solution Oral 250 mg Tablet, chewable Oral Capsule Oral Tablet, chewable Oral 5000 IU - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Decomposes at 350 NIOSH [L781] boiling point (°C) Decomposes NIOSH [L781] water solubility 0.1g/L NIOSH [L781] - Predicted Properties
Property Value Source Water Solubility 226.0 mg/mL ALOGPS logP 0.52 ALOGPS logP 0.25 ChemAxon logS 0.21 ALOGPS pKa (Strongest Acidic) 6.05 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 63.19 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 31.17 m3·mol-1 ChemAxon Polarizability 3.52 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Targets
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Blocker
- General Function
- Voltage-gated cation channel activity
- Specific Function
- NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...
Components:
References
- Nikolaev MV, Magazanik LG, Tikhonov DB: Influence of external magnesium ions on the NMDA receptor channel block by different types of organic cations. Neuropharmacology. 2012 Apr;62(5-6):2078-85. doi: 10.1016/j.neuropharm.2011.12.029. Epub 2012 Jan 12. [PubMed:22261381]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Protein serine/threonine kinase activity
- Specific Function
- Essential ion channel and serine/threonine-protein kinase. Crucial for magnesium homeostasis. Has an important role in epithelial magnesium transport and in the active magnesium absorption in the g...
- Gene Name
- TRPM6
- Uniprot ID
- Q9BX84
- Uniprot Name
- Transient receptor potential cation channel subfamily M member 6
- Molecular Weight
- 231705.935 Da
References
- Jahnen-Dechent W, Ketteler M: Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163. [PubMed:26069819]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Cation transmembrane transporter activity
- Specific Function
- Not Available
- Gene Name
- SLC41A3
- Uniprot ID
- Q96GZ6
- Uniprot Name
- Solute carrier family 41 member 3
- Molecular Weight
- 54766.1 Da
References
- de Baaij JH: The art of magnesium transport. Magnes Res. 2015 Jul-Sep;28(3):85-91. doi: 10.1684/mrh.2015.0388. [PubMed:26446763]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Magnesium ion transmembrane transporter activity
- Specific Function
- Divalent metal cation transporter. Mediates transport of divalent metal cations in an order of Mg(2+) > Co(2+) > Mn(2+) > Sr(2+) > Ba(2+) > Cu(2+) > Fe(2+) (By similarity).
- Gene Name
- CNNM2
- Uniprot ID
- Q9H8M5
- Uniprot Name
- Metal transporter CNNM2
- Molecular Weight
- 96622.35 Da
References
- de Baaij JH: The art of magnesium transport. Magnes Res. 2015 Jul-Sep;28(3):85-91. doi: 10.1684/mrh.2015.0388. [PubMed:26446763]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Protein serine/threonine kinase activity
- Specific Function
- Essential ion channel and serine/threonine-protein kinase. Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the regulation of anoxi...
- Gene Name
- TRPM7
- Uniprot ID
- Q96QT4
- Uniprot Name
- Transient receptor potential cation channel subfamily M member 7
- Molecular Weight
- 212695.37 Da
References
- Jahnen-Dechent W, Ketteler M: Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163. [PubMed:26069819]
Drug created on November 30, 2015 12:10 / Updated on December 11, 2020 14:57